N-Formyl-Met-Leu-Phe Protein
A Potent Agonist of FPR1 G-Protein Coupled Receptor
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Storage | -20°C |
---|---|
Precautions | N-Formyl-Met-Leu-Phe Protein is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Chemotactic factors from both Gram-positive and Gram-negative bacteria are short peptides with N-formyl methionine at the N-terminus (extensively reviewed in reference 1). These peptides are released from bacteria during infection and activate formyl peptide receptor (FPR), a member of G-protein coupled receptors (GPCRs). In human, the FPR family consists mainly of three receptors, FPR1, FPR2/ALX (formerly FPRL1), and FPR3 (formerly FPRL2) which all couple to the Gi subtype of G-proteins and ultimately lead to the activation of phospholipase C and intracellular Ca2+increase1,2.
N-Formyl-Met-Leu-Phe is a selective and potent agonist of the Formylpeptide receptor (FPR1)3.
In human polymorphonuclear leukocytes N-formyl-met-leu-phe activates p38 by a process involving phosphatidylinositol 3-kinase, protein kinase C, and calcium4. N-Formyl-Met-Leu-Phe increased in a dose-dependent manner (0.1 nM – 1 µM) the adherence of neutrophils to vascular endothelial cells which is the initial event in the migration of neutrophils through blood vessel walls to tissue sites of inflammation5.
References
1 . Ye, R.D. et al.(2009)Pharmacol. Rev.61, 119.
2 . Le, Y. et al.(2002)Trends Immunol. 23, 541.
3 . Showell, H.J. et al. (1976)J. Exp. Med 143,1154.
4 . Krump, E. et al.(1997)J. Biol. Chem.272, 937.
5 . Tonnesen, M.G. et al. (1984)J. Clin. Invest. 74,1581.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.